Sanofi’s shares have pulled back sharply in recent sessions and are now hovering close to a significant medium‑term support zone near €77.1. This price area has historically acted as a floor, and a bounce could spark renewed buying interest.
Should the stock hold above the €77.1 mark, technical analysts anticipate a possible move toward the next resistance around €85. The psychological effect of staying above the support may also revive consensus among buyers, creating a modest upward thrust.
For investors looking to capitalize on this upside, the Vontobel call warrant BC20V offers an attractive levered exposure. Priced at €1.17, the warrant targets a 40 % upside if Sanofi climbs to the €85 level. Its built‑in stop‑loss sits near €74, limiting the maximum loss to roughly 25 % of the premium paid.
While the warrant presents a compelling risk‑reward profile, investors should remember that market conditions can shift quickly. Continuous monitoring of Sanofi’s price action and broader sector sentiment is essential before committing capital.
Our team monitors the underlying products and will update the recommendation as market dynamics evolve. Targets and stop levels are provided for informational purposes and may be adjusted according to our latest outlook.